Objective
to establish the clinical benefit of PCI of CTO compared to no PCI of CTO with the option for PCI of obstructive non-CTO lesions and medical treatment
Study
open-label multicentre, randomised non-inferiority trial
Population
patients with silent ischaemia, stable angina or acute coronary syndrome and a denovo CTO (3 months)
Endpoints
composite of death, MI, stroke or any revascularisation during a mean follow-up 4.0 years
Conclusion
there was no difference in the incidence of major cardiac adverse events with CTO-PCI as compared to no CTO-PCI at a median follow-up of 4 years
Lee et al. Circulation. 2019;139:1674-83
